Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Miami, FL, US. The stock last traded at $17.28, down 1.85% on the session, giving a market capitalisation of $13.79B. On trailing twelve-month figures it carries a trailing P/E of -15.43, a net margin of 0.0%. Its beta of -1.24 implies it has historically moved less than the broad market.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Summit Therapeutics Inc. is most often compared with the following Healthcare names: